Alejandro Sanchez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alejandro Sanchez has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Abraham Ari Hakimi
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, USA
17 shared publications - Andrea Knezevic
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
17 shared publications - Helena Furberg
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
17 shared publications - Jessica M. Scott
Memorial Sloan Kettering Cancer Center, New York, NY
17 shared publications - Marina Mourtzakis
University of Waterloo
17 shared publications - Oguz Akin
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
17 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 4 (9)
Salvage Metastasis-Directed Therapy Without Androgen Deprivation for Positron Emission Tomography–Defined Oligorecurrent Prostate Cancer: Results of the SOAR Phase II Trial
Purpose: Advanced molecular imaging has enabled detection of oligorecurrent prostate cancer (PCa) at low PSA levels, but optimal management of positron emission tomography (PET)–defined recurrence remains uncertain. We conducted a phase II trial to evaluate biochemical response, oncologic outcomes, and safety of salvage metastasis-directed therapy (MDT) delivered without concurrent androgen deprivation therapy (ADT). Materials and Methods: Twenty men with PET-defined oligometastatic recurrence (≤ 10 nodal or osseous lesions) after radical prostatectomy were prospectively enrolled (2019-2023). Treatment was assigned based on disease distribution: bone-directed radiotherapy (arm A), salvage lymph node dissection (sLND; arm B), or combined therapy (arm C). The primary endpoint was a ≥ 50% PSA decline at 6 months; secondary endpoints included PSA progression, ADT-free survival, and treatment-related morbidity. Results: The median age was 65 years (IQR 61.5-70.0); 18 patients had nodal-only recurrence, and 2 had bone-only disease. At 6 months, 8 of 20 patients (40%) achieved ≥ 50% PSA reduction. Over a median follow-up of 11.4 months, 12-month PSA-PFS was 74.1% (95% confidence interval [CI] 54.8%-100%) and ADT-free survival was 71.4% (95% CI 52.7%-96.6%), with a median of 13.3 months. Among sLND patients, pathologic carcinoma was confirmed in 15 of 18 (83%) and pathologic assessment frequently revealed more extensive nodal disease than predicted by PET. No Clavien-Dindo grade III-V complications occurred. Conclusions: Salvage MDT without ADT is feasible, safe, and associated with meaningful biochemical responses in selected patients with PET-defined oligorecurrent PCa. Pathologic findings demonstrate that PET imaging may underestimate true nodal disease burden, supporting comprehensive treatment strategies and further prospective investigation.
- 1 September 2026
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 4 (9)
Open AccessSalvage Metastasis-Directed Therapy Without Androgen Deprivation for Positron Emission Tomography–Defined Oligorecurrent Prostate Cancer: Results of the SOAR Phase II Trial
Purpose: Advanced molecular imaging has enabled detection of oligorecurrent prostate cancer (PCa) at low PSA levels, but optimal management of positron emission tomography (PET)–defined recurrence remains uncertain. We conducted a phase II trial to evaluate biochemical response, oncologic outcomes, and safety of salvage metastasis-directed therapy (MDT) delivered without concurrent androgen deprivation therapy (ADT). Materials and Methods: Twenty men with PET-defined oligometastatic recurrence (≤ 10 nodal or osseous lesions) after radical prostatectomy were prospectively enrolled (2019-2023). Treatment was assigned based on disease distribution: bone-directed radiotherapy (arm A), salvage lymph node dissection (sLND; arm B), or combined therapy (arm C). The primary endpoint was a ≥ 50% PSA decline at 6 months; secondary endpoints included PSA progression, ADT-free survival, and treatment-related morbidity. Results: The median age was 65 years (IQR 61.5-70.0); 18 patients had nodal-only recurrence, and 2 had bone-only disease. At 6 months, 8 of 20 patients (40%) achieved ≥ 50% PSA reduction. Over a median follow-up of 11.4 months, 12-month PSA-PFS was 74.1% (95% confidence interval [CI] 54.8%-100%) and ADT-free survival was 71.4% (95% CI 52.7%-96.6%), with a median of 13.3 months. Among sLND patients, pathologic carcinoma was confirmed in 15 of 18 (83%) and pathologic assessment frequently revealed more extensive nodal disease than predicted by PET. No Clavien-Dindo grade III-V complications occurred. Conclusions: Salvage MDT without ADT is feasible, safe, and associated with meaningful biochemical responses in selected patients with PET-defined oligorecurrent PCa. Pathologic findings demonstrate that PET imaging may underestimate true nodal disease burden, supporting comprehensive treatment strategies and further prospective investigation.
- Open Access
- 24 June 2026
- Published by Elsevier in Urology Case Reports
- Vol. 67, 103522
Advanced pelvic paraganglioma presenting as hematuria and urinary retention with a large intravesical mass: A case report
- 24 June 2026
- Published by Elsevier in Urology Case Reports
- Vol. 67, 103522
Open AccessAdvanced pelvic paraganglioma presenting as hematuria and urinary retention with a large intravesical mass: A case report
- Open Access
- 31 March 2026
- Published by Elsevier in Journal of the Academy of Nutrition and Dietetics
- Vol. 126 (8) , 156351
Dietary Patterns Associated With Weight Loss Among Patients With Colorectal Cancer During the First 6 Months After Diagnosis: A Cross-Sectional Analysis From the ColoCare Study
- 31 March 2026
- Published by Elsevier in Journal of the Academy of Nutrition and Dietetics
- Vol. 126 (8) , 156351
Open AccessDietary Patterns Associated With Weight Loss Among Patients With Colorectal Cancer During the First 6 Months After Diagnosis: A Cross-Sectional Analysis From the ColoCare Study
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S6-S8 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
Table S6. Associations between SMI and length of prior treatment exposure before starting ICB among the 144 patients that received ICB in the second+ line setting Table S7. The prevalence of SMI by the number of prior treatments received before starting ICB among the 144 patients that received ICB in the second+ line setting Table S8. Characteristics of the TCGA cohort used for gene expression analysis by SMI
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S6-S8 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
Table S6. Associations between SMI and length of prior treatment exposure before starting ICB among the 144 patients that received ICB in the second+ line setting Table S7. The prevalence of SMI by the number of prior treatments received before starting ICB among the 144 patients that received ICB in the second+ line setting Table S8. Characteristics of the TCGA cohort used for gene expression analysis by SMI
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S3 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
Associations of Body Composition and PFS
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S3 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
Associations of Body Composition and PFS
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S5 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
Associations of Body Composition and Clinical Characteristics
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S5 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
Associations of Body Composition and Clinical Characteristics
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
Purpose:High body mass index (BMI) may lead to improved immune-checkpoint blockade (ICB) outcomes in metastatic clear cell renal cell carcinoma (mccRCC). However, BMI is a crude body size measure. We investigated BMI and radiographically assessed body composition (BC) parameters association with mccRCC ICB outcomes.Experimental Design:Retrospective study of ICB-treated patients with mccRCC. BMI and BC variables [skeletal muscle index (SMI) and multiple adiposity indexes] were determined using pretreatment CT scans. We examined the associations between BMI and BC variables with ICB outcomes. Therapeutic responses per RECIST v1.1 were determined. We compared whole-transcriptomic patterns with BC variables in a separate cohort of 62 primary tumor samples.Results:205 patients with mccRCC were included in the cohort (74% were male, 71% were overweight/obese, and 53% were classified as low SMI). High-BMI patients experienced longer overall survival (OS) than normal-weight patients [unadjusted HR, 0.66; 95% confidence interval (CI), 0.45–0.97; P = 0.035]. The only BC variable associated with OS was SMI [unadjusted HR comparing low vs. high SMI 1.65 (95% CI: 1.13–2.43); P = 0.009]. However, this OS association became nonsignificant after adjusting for International Metastatic Renal Cell Carcinoma Database Consortium score and line of therapy. No OS association was seen for adiposity and no BC variable was associated with progression-free survival or radiological responses. Tumors from patients with low SMI displayed increased angiogenic, inflammatory, and myeloid signals.Conclusions:Our findings highlight the relevance of skeletal muscle in the BMI paradox. Future studies should investigate if addressing low skeletal muscle in metastatic patients treated with ICB can improve survival.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
Purpose:High body mass index (BMI) may lead to improved immune-checkpoint blockade (ICB) outcomes in metastatic clear cell renal cell carcinoma (mccRCC). However, BMI is a crude body size measure. We investigated BMI and radiographically assessed body composition (BC) parameters association with mccRCC ICB outcomes.Experimental Design:Retrospective study of ICB-treated patients with mccRCC. BMI and BC variables [skeletal muscle index (SMI) and multiple adiposity indexes] were determined using pretreatment CT scans. We examined the associations between BMI and BC variables with ICB outcomes. Therapeutic responses per RECIST v1.1 were determined. We compared whole-transcriptomic patterns with BC variables in a separate cohort of 62 primary tumor samples.Results:205 patients with mccRCC were included in the cohort (74% were male, 71% were overweight/obese, and 53% were classified as low SMI). High-BMI patients experienced longer overall survival (OS) than normal-weight patients [unadjusted HR, 0.66; 95% confidence interval (CI), 0.45–0.97; P = 0.035]. The only BC variable associated with OS was SMI [unadjusted HR comparing low vs. high SMI 1.65 (95% CI: 1.13–2.43); P = 0.009]. However, this OS association became nonsignificant after adjusting for International Metastatic Renal Cell Carcinoma Database Consortium score and line of therapy. No OS association was seen for adiposity and no BC variable was associated with progression-free survival or radiological responses. Tumors from patients with low SMI displayed increased angiogenic, inflammatory, and myeloid signals.Conclusions:Our findings highlight the relevance of skeletal muscle in the BMI paradox. Future studies should investigate if addressing low skeletal muscle in metastatic patients treated with ICB can improve survival.
- 11 August 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (11) , 2308-2316
Prostate Cancer Imaging Stewardship: a multimodal, physician-centered intervention for guideline-concordant imaging
Background: Inappropriate imaging to stage low-risk prostate cancer is considered low-value care. Determining the effectiveness of a theory-based intervention—Prostate Cancer Imaging Stewardship (PCIS)—to promote guideline-concordant imaging. Methods: A stepped-wedge, cluster-randomized trial, PCIS, was conducted between March 2018 and March 2021 at 10 Veterans Health Administration medical centers (VAMCs) initially selected for prostate cancer volume, geographic diversity, and willingness to participate. Intervention initiations at sites were randomized in 3-month intervals. We enrolled 61 urology providers who treat prostate cancer at participating sites. Outcomes were assessed among 2302 patients with incident prostate cancer aged 18-85 years. PCIS combines 3 evidence-based provider-focused behavior change strategies: (1) Clinical Reminder Order Check triggered when a provider attempted to order imaging for a patient with prostate-specific antigen < 20 ng/mL, (2) VAMC-level academic detailing at initiation and every 3 months thereafter, and (3) Audit and Feedback for providers to improve their imaging performance. The main outcome was guideline-discordant nuclear medicine bone scan (NMBS) imaging for low-risk prostate cancer patients. Results: NMBS imaging would be consistent with National Comprehensive Cancer Network guidelines in 878 patients (38%) and inconsistent in 1424 patients (62%). Among patients not requiring NMBS, 141/690 (20.4%) received guideline-discordant imaging (ie, NMBS ordered) during Control compared with 109/734 (14.9%) during Intervention (odds ratio [OR] = 0.54, P = .04). Among patients requiring a NMBS, 29 of 425 (6.8%) did not receive one (ie, guideline-discordant imaging) during Control compared with 25 of 453 (5.5%) during the Intervention (OR = 1.36, P = .36). Conclusion: PCIS significantly reduced low-value, guideline-discordant NMBS imaging among low-risk prostate cancer patients without negatively affecting necessary imaging for high-risk patients. Clinical Trials Registration: NCT03445559.
- 11 August 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (11) , 2308-2316
Prostate Cancer Imaging Stewardship: a multimodal, physician-centered intervention for guideline-concordant imaging
Background: Inappropriate imaging to stage low-risk prostate cancer is considered low-value care. Determining the effectiveness of a theory-based intervention—Prostate Cancer Imaging Stewardship (PCIS)—to promote guideline-concordant imaging. Methods: A stepped-wedge, cluster-randomized trial, PCIS, was conducted between March 2018 and March 2021 at 10 Veterans Health Administration medical centers (VAMCs) initially selected for prostate cancer volume, geographic diversity, and willingness to participate. Intervention initiations at sites were randomized in 3-month intervals. We enrolled 61 urology providers who treat prostate cancer at participating sites. Outcomes were assessed among 2302 patients with incident prostate cancer aged 18-85 years. PCIS combines 3 evidence-based provider-focused behavior change strategies: (1) Clinical Reminder Order Check triggered when a provider attempted to order imaging for a patient with prostate-specific antigen < 20 ng/mL, (2) VAMC-level academic detailing at initiation and every 3 months thereafter, and (3) Audit and Feedback for providers to improve their imaging performance. The main outcome was guideline-discordant nuclear medicine bone scan (NMBS) imaging for low-risk prostate cancer patients. Results: NMBS imaging would be consistent with National Comprehensive Cancer Network guidelines in 878 patients (38%) and inconsistent in 1424 patients (62%). Among patients not requiring NMBS, 141/690 (20.4%) received guideline-discordant imaging (ie, NMBS ordered) during Control compared with 109/734 (14.9%) during Intervention (odds ratio [OR] = 0.54, P = .04). Among patients requiring a NMBS, 29 of 425 (6.8%) did not receive one (ie, guideline-discordant imaging) during Control compared with 25 of 453 (5.5%) during the Intervention (OR = 1.36, P = .36). Conclusion: PCIS significantly reduced low-value, guideline-discordant NMBS imaging among low-risk prostate cancer patients without negatively affecting necessary imaging for high-risk patients. Clinical Trials Registration: NCT03445559.